Literature DB >> 15308348

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

Maria Teresa Maggiorella1, Silvia Baroncelli, Zuleika Michelini, Emanuele Fanales-Belasio, Sonia Moretti, Leonardo Sernicola, Andrea Cara, Donatella R M Negri, Stefano Buttò, Valeria Fiorelli, Antonella Tripiciano, Arianna Scoglio, Antonella Caputo, Alessandra Borsetti, Barbara Ridolfi, Roberta Bona, Peter ten Haaft, Iole Macchia, Pasqualina Leone, Maria Rosaria Pavone-Cossut, Filomena Nappi, Massimo Ciccozzi, Jonathan Heeney, Fausto Titti, Aurelio Cafaro, Barbara Ensoli.   

Abstract

Vaccination with a biologically active Tat protein or tat DNA contained infection with the highly pathogenic SHIV89.6P virus, preventing CD4 T-cell decline and disease onset. Here we show that protection was prolonged, since neither CD4 T-cell decline nor active virus replication was observed in all vaccinated animals that controlled virus replication up to week 104 after the challenge. In contrast, virus persisted and replicated in peripheral blood mononuclear cells and lymph nodes of infected animals, two of which died. Tat-specific antibody, CD4 and CD8 T-cell responses were high and stable only in the animals controlling the infection. In contrast, Gag-specific antibody production and CD4 and CD8 T-cell responses were consistently and persistently positive only in the monkeys that did not control primary virus replication. These results indicate that vaccination with Tat protein or DNA induced long-term memory Tat-specific immune responses and controlled primary infection at its early stages allowing a long-term containment of virus replication and spread in blood and tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308348     DOI: 10.1016/j.vaccine.2004.03.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Authors:  Ruth H Florese; Roger W Wiseman; David Venzon; Julie A Karl; Thorsten Demberg; Kay Larsen; Leon Flanary; V S Kalyanaraman; Ranajit Pal; Fausto Titti; L Jean Patterson; Megan J Heath; David H O'Connor; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

3.  Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Authors:  Valentina Finessi; Francesco Nicoli; Eleonora Gallerani; Fabio Sforza; Mariaconcetta Sicurella; Aurelio Cafaro; Antonella Caputo; Barbara Ensoli; Riccardo Gavioli
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).

Authors:  Sergio Rosales-Mendoza; Néstor Rubio-Infante; Dania O Govea-Alonso; Leticia Moreno-Fierros
Journal:  Plant Cell Rep       Date:  2011-12-13       Impact factor: 4.570

5.  Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Authors:  Xiaoping Liang; Danilo R Casimiro; William A Schleif; Fubao Wang; Mary-Ellen Davies; Zhi-Qiang Zhang; Tong-Ming Fu; Adam C Finnefrock; Larry Handt; Michael P Citron; Gwendolyn Heidecker; Aimin Tang; Minchun Chen; Keith A Wilson; Lori Gabryelski; Michael McElhaugh; Anthony Carella; Cheryl Moyer; Lingyi Huang; Salvatore Vitelli; Deepa Patel; Jing Lin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

8.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

10.  Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice.

Authors:  Yuri Jorge Peña Ramírez; Ennio Tasciotti; Abel Gutierrez-Ortega; Alberto J Donayre Torres; María Teresa Olivera Flores; Mauro Giacca; Miguel Angel Gómez Lim
Journal:  Clin Vaccine Immunol       Date:  2007-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.